Reyna Chavarri
Physician Assistant · Edinburg, TXNPI 1457005456
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $28.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Amgen$757
- Aurinia Pharma U.S., Inc.$522
- ANI Pharmaceuticals, Inc.$466
- AstraZeneca$466
- UCB, Inc.$371
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,84594%
- Education$3676%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 32 | $1,334 |
| Amgen(2 entities) | 38 | $757 |
| Aurinia Pharma U.S., Inc. | 30 | $522 |
| ANI Pharmaceuticals, Inc. | 17 | $466 |
| AstraZeneca(2 entities) | 6 | $466 |
| UCB, Inc. | 5 | $371 |
| AbbVie | 14 | $366 |
| Radius Health, Inc. | 7 | $334 |
| Lilly USA, LLC | 15 | $251 |
| Novartis | 10 | $214 |
| Janssen Scientific Affairs, LLC | 2 | $196 |
| E.r. Squibb & Sons, L.L.C. | 20 | $193 |
| Sanofi | 2 | $151 |
| GSK | 3 | $143 |
| Merck | 1 | $78 |
| Organon | 4 | $74 |
| Fresenius Kabi USA, LLC | 2 | $54 |
| Pfizer | 3 | $45 |
| Argenx US, Inc. | 1 | $33 |
| Boehringer Ingelheim | 1 | $29 |
| Abbott | 1 | $25 |
| Optinose US, Inc. | 1 | $24 |
| Phadia US Inc. | 1 | $21 |
| Octapharma USA, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIMPONI ARIA$654
- Tremfya$538
- SAPHNELO$346
- LUPKYNIS$236
- PURIFIED CORTROPHIN GEL$218
- Tavneos$131
- VRAYLAR$125
- Bimzelx$125
- KEVZARA$121
- BENLYSTA$108
How this compares
$6,212 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 60 | $446,878 |
| Humira(Cf) PenAdalimumab | 51 | $340,751 |
| Enbrel MiniEtanercept | 35 | $281,915 |
| RinvoqUpadacitinib | 38 | $259,000 |
| Cosentyx Unoready PenSecukinumab | 26 | $242,292 |
| Xeljanz XrTofacitinib Citrate | 20 | $112,155 |
| Taltz AutoinjectorIxekizumab | 16 | $106,959 |
| Cyltezo(Cf)Adalimumab-Adbm | 13 | $84,610 |
| Humira(Cf)Adalimumab | 12 | $82,617 |
| Orencia ClickjectAbatacept | 15 | $80,790 |
| Cimzia (2 Pack)Certolizumab Pegol | 13 | $71,527 |
| OtezlaApremilast | 13 | $62,423 |
| Teriparatide | 12 | $21,159 |
| Hydroxychloroquine Sulfate | 352 | $16,187 |
| Leflunomide | 159 | $11,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $366 | $341,61850 claims |
| Boehringer IngelheimCyltezo(Cf) | $29 | $84,61013 claims |
| UCB, Inc.Cimzia (2 Pack) | $371 | $71,52713 claims |
| AmgenOtezla | $757 | $62,42313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Edinburg
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
- Heidi JeffreysLubbock$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.